down arrow

Karuna Therapeutics, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US48576A1007
USD
329.83
0.00 (0.00%)

Mar 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

158.57329.99
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2023)

FII

12.15%

Held by 147 FIIs

DII

30.41%

Held by 51 DIIs

Promoter

10.30%

How big is Karuna Therapeutics, Inc.?

22-Jun-2025

As of Mar 19, Karuna Therapeutics, Inc. has a market capitalization of $12.58 billion, with net sales of $0.65 million and a net profit of -$433.67 million over the last four quarters. Shareholder's funds total $1.25 billion, and total assets are $1.34 billion as of Dec 23.

As of Mar 19, Karuna Therapeutics, Inc. has a market capitalization of 12,582.24 million, categorizing it as a Mid Cap company.<BR><BR>As of Mar 19, the sum of net sales for the latest four quarters is 0.65 million, while the sum of net profit for the same period is -433.67 million.<BR><BR>As of Dec 23, the shareholder's funds amount to 1,254.23 million, and total assets are reported at 1,336.21 million.

Read More

What does Karuna Therapeutics, Inc. do?

22-Jun-2025

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric conditions, with a market cap of approximately $12.58 billion and a recent net profit of -$114 million. The company is classified as mid-cap and operates within the pharmaceuticals industry.

Overview:<BR>Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for disabling neuropsychiatric conditions, operating within the Pharmaceuticals: Major industry and classified as a mid-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -114 Million (Quarterly Results - Dec 2023) <BR>Market-cap: USD 12,582.24 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 98.79% <BR>Debt Equity: -1.00 <BR>Return on Equity: -34.58% <BR>Price to Book: 10.03<BR><BR>Contact Details:<BR>Address: 33 Arch St Ste 3110, BOSTON MA: 02110-1424 <BR>Tel: 1 857 4492244 <BR>Fax: 1 302 6555049 <BR>Website: https://karunatx.com/

Read More

Who are in the management team of Karuna Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Karuna Therapeutics, Inc. includes Dr. Steven Paul as Chairman, President, and CEO, along with Board members Dr. Jeffrey Jonas, Ms. Laurie Olson, Ms. Denice Torres, Dr. David Wheadon, and Independent Director Mr. Christopher Coughlin.

As of March 2022, the management team of Karuna Therapeutics, Inc. includes Dr. Steven Paul, who serves as the Chairman of the Board, President, and Chief Executive Officer. Other members of the Board of Directors are Dr. Jeffrey Jonas, Ms. Laurie Olson, Ms. Denice Torres, Dr. David Wheadon, and Mr. Christopher Coughlin, who is an Independent Director.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 12,582 Million (Mid Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

98.79%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-34.58%

stock-summary
Price to Book

10.03

Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2023)
Net Profit:
-114 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
50.58%
0%
50.58%
6 Months
88.86%
0%
88.86%
1 Year
72.12%
0%
72.12%
2 Years
179.9%
0%
179.9%
3 Years
182.65%
0%
182.65%
4 Years
411.05%
0%
411.05%
5 Years
0%
0%
0.0%

Karuna Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
13.34%
EBIT Growth (5y)
-272.70%
EBIT to Interest (avg)
-209.11
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.04
Tax Ratio
0.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.03
EV to EBIT
-22.88
EV to EBITDA
-22.96
EV to Capital Employed
-1974.24
EV to Sales
11322.27
PEG Ratio
NA
Dividend Yield
98.79%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-34.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 88 Schemes (47.14%)

Foreign Institutions

Held by 147 Foreign Institutions (12.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 4.45% vs -15.41% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-129.10",
          "val2": "-135.80",
          "chgp": "4.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-113.80",
          "val2": "-119.10",
          "chgp": "4.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -93.40% vs -71.35% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -56.97% vs -92.14% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "10.60",
          "chgp": "-93.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-493.10",
          "val2": "-288.60",
          "chgp": "-70.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-433.70",
          "val2": "-276.30",
          "chgp": "-56.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-756,539.80%",
          "val2": "-27,232.90%",
          "chgp": "-72,930.69%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQstock-summary
Dec'23
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-129.10
-135.80
4.93%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-113.80
-119.10
4.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is 4.45% vs -15.41% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.70
10.60
-93.40%
Operating Profit (PBDIT) excl Other Income
-493.10
-288.60
-70.86%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-433.70
-276.30
-56.97%
Operating Profit Margin (Excl OI)
-756,539.80%
-27,232.90%
-72,930.69%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -93.40% vs -71.35% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -56.97% vs -92.14% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Karuna Therapeutics, Inc. stock-summary
stock-summary
Karuna Therapeutics, Inc.
Pharmaceuticals: Major
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.
Company Coordinates stock-summary
Company Details
33 Arch St Ste 3110 , BOSTON MA : 02110-1424
stock-summary
Tel: 1 857 4492244
stock-summary
https://karunatx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."